No Data
No Data
Q32 Bio Inc. Patent Woes: Navigating the Perilous Waters of Intellectual Property Disputes
Q32 Bio Initiated at Overweight by Wells Fargo
Q32 Bio Analyst Ratings
Wells Fargo Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $95
Q32 Bio to Participate in Upcoming September Investor Conferences
Piper Sandler Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $60